Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Evaxion announces business update and second quarter 2026 financial results
August 20, 2026 7:30 AM EDTCOPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business update and announces second quarter 2026 financial results.
Business highlights (since last quarterly update)
Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include:



